News

February 01, 2024

TD2 Expands Preclinical and Clinical Services by Acquiring Flow Contract Site Laboratory (FCSL)

SCOTTSDALE, ARIZONA, USA, February 1, 2024 /EINPresswire.com/ -- Translational Drug Development (TD2), a leading provider of comprehensive preclinical drug development, translational and clinical trial services, is pleased to announce its acquisition of Flow Contract Site Laboratory (FCSL) located in Bothell,...

December 05, 2023

TD2 to Highlight Development of a Dual-Specific Inhibitor for Treatment of Primary Myelofibrosis at ASH Annual Meeting

SCOTTSDALE, ARIZONA, USA, December 5, 2023 /EINPresswire.com/ Translational Drug Development (TD2), a precision oncology contract research organization (CRO), announces the presentation of preclinical results of RR-1752, a targeted inhibitor of ROCK/AURK, for primary myelofibrosis at the American Society of Hematology...

August 17, 2023

Qualigen Therapeutics Partners with TD2 for Phase 1 Clinical Development of QN-302 for the Treatment of Advanced or Metastatic Solid Tumors

CARLSBAD, Calif., Aug. 17, 2023 (GLOBE NEWSWIRE) Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, announced today it is partnering with Translational Drug Development...

May 17, 2023

Tara Franks, Chief Operating Officer of TD2, recognized as a 2023 Phoenix Titan 100

SCOTTSDALE, ARIZONA, UNITED STATES, May 17, 2023 / EINPresswire.com/ -- Titan CEO and headline sponsor Wipfli LLP are pleased to announce Tara Franks, Chief Operating Officer of Translational Drug Development (TD2), as a 2023 Phoenix Titan 100. The Titan 100...

April 11, 2023

TD2 to Highlight the Development of a Novel Metabolomic Cancer Model at the AACR Annual Meeting 2023

SCOTTSDALE, ARIZONA, UNITED STATES, April 11, 2023/EINPresswire.com/ -- Translational Drug Development (TD2), a precision oncology contract research organization (CRO), announces the presentation of their preclinical development of a novel Diet-Induced Obesity Model for antitumor, proteomic, and metabolomic studies at the...

October 05, 2022

TD2 Announces Dr. Alan Miller as New Chief Medical Officer

The respected Medical Oncology leader brings extensive experience as TD2 continues its strategic growth. SCOTTSDALE, ARIZONA, UNITED STATES, October 5, 2022 /EINPresswire.com/ -- Translational Drug Development (TD2), a precision oncology contract research organization (CRO), announces the addition of Dr. Alan...

August 25, 2022

SELLAS Life Sciences’ Highly Selective CDK9 Inhibitor, GFH009, Demonstrates Cancer Cell Growth Inhibition in Preclinical In Vitro Model of Neuroendocrine Prostate Cancer Cell Line

NEW YORK, Aug. 24, 2022 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced...

August 09, 2022

SELLAS Life Sciences’ GFH009 Demonstrates Cancer Cell Growth Inhibition in Preclinical In Vitro Studies in Solid Cancer and Acute Myeloid Leukemia Cell Lines

NEW YORK, Aug. 09, 2022 (GLOBE NEWSWIRE) – SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS" or the "Company"), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced...

May 12, 2022

Genzada Pharmaceuticals Opens Phase 1B Metastatic Breast Cancer Trial

HUTCHINSON, Kan. – May 12, 2022 – Genzada Pharmaceuticals USA Inc. (Genzada), a subsidiary of Ionics Pharmaceuticals SA, announced today the official opening of a Phase 1B clinical trial for the oral therapeutic GZ17-6.02 (6.02) in combination with capecitabine in...

April 05, 2022

TD2 to Highlight Preclinical Progress of Two Novel HDAC Inhibitors at AACR Annual Meeting

SCOTTSDALE, ARIZONA, UNITED STATES, April 5, 2022 /EINPresswire.com/ -- Translational Drug Development (TD2), a precision oncology contract research organization (CRO), announces the presentation of the preclinical results of two novel, targeted epigenetic inhibitors at the American Association for Cancer Research...

Load More

Events

January 30, 2024

Tumor Models SF

Grand Hyatt at SFO | San Francisco, CA

Learn more +

February 27, 2024

IO 360

NY Marriott At The Brooklyn Bridge | Brooklyn, NY

Learn more +

April 5, 2024

AACR

San Diego Convention Center | San Diego, CA

Learn more +

STAY IN TOUCH

Get free tips, tools and resources by subscribing to the TD2 newsletter.

Skip to content